SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lenchik L, Kiebzak GM, Blunt BA, International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. 2002 What is the role of serial bone mineral density measurements in patient management ? J Clin Densitom 5 (Suppl): S29S38.
  • 2
    2008 Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, DC, USA.
  • 3
    Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA, AACE Osteoporosis TF 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9: 544564.
  • 4
    Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D Fracture Intervention Trial Research Group 2000 Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. JAMA 283: 13181321.
  • 5
    Bonnick SL 2000 Monitoring osteoporosis therapy with bone densitometry: A vital tool or regression toward mediocrity ? J Clin Endocrinol Metab 85: 34933495.
  • 6
    Lenchik L, Watts NB 2000 Regression to the mean: What does it mean? Using bone density results to monitor treatment of osteoporosis. J Clin Densitom 4: 144.
  • 7
    Bell KJL, Hayden A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC 2009 Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: Secondary analysis of trial data. BMJ 338: b2266.
  • 8
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 15351541.
  • 9
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, Fracture Intervention Trial Research Group. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. JAMA 280: 20772082.
  • 10
    PROGRESS Collaborative Group 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 10331041.
  • 11
    Bell KJ, Haven A, Macaskill P, Craig JC, Neal BC, Irwig L 2009 Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. J Clin Epidemiol 62: 650659.
  • 12
    Lewiecki EM, Binkley N 2009 Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr Pract 15: Epub ahead of print.
  • 13
    Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 12541259.
  • 14
    Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85: 231236.
  • 15
    Faulkner KG 2000 Bone matters: Are density increases necessary to reduce fracture risk ? J Bone Miner Res 15: 183187.
  • 16
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D Fracture Intervention Trial Research Group. 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42: 12461254.
  • 17
    Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7: 252261.
  • 18
    Chapurlat RD, Palermo L, Ramsay P, Cummings SR 2005 Risk of fracture among women who lose bone density during treatment with alendronate: The Fracture Intervention Trial. Osteoporos Int 16: 842848.
  • 19
    Dowd R, Recker RR, Heaney RP 2000 Study subjects and ordinary patients. Osteoporos Int 11: 533536.
  • 20
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81: 10131022.
  • 21
    Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87: 44314437.
  • 22
    LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J 1999 Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 281: 15051511.
  • 23
    Lewiecki EM, Rudolph LA 2002 How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis ? J Bone Miner Res 17: S2; S367.
  • 24
    Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SAM, Sebba A, Kagan R, Chen E, Thompson DE, De Papp AE, FACT Investigators 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91: 26312637.
  • 25
    Bonnick SL, Shulman L 2006 Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both ? Am J Med 119: 25S31S.
  • 26
    Dansereau R, Crail D 2009 Differences in disintegration rates with generic alendronate. J Clin Densitom (in press).
  • 27
    Ringe JD, Moller G 2009 Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective pateint chart review analysis. Rheumatol Int (in press).
  • 28
    Lenchik L, Leib ES, Hamdy RC, Binkley NC, Miller PD, Watts NB 2002 Executive summary, International Society for Clinical Densitometry Position Development Conference, Denver, Colorado, July 20-22, 2001. J Clin Densitom 5 (Suppl): S1S3.
  • 29
    Clowes JA, Peel NF, Eastell R 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 83: 11171123.
  • 30
    Delmas PD, Vrijens B, Eastell R, Roux C, Pols HAP, Ringe JD, Grauer A, Cahall D, Watts NB 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92: 12961304.